Top-News
Pharmazeutika USA

Palatin Technologies News

Aktie
WKN:  A3DTUW ISIN:  US6960775020 US-Symbol:  PTN
2,01 €
+0,068 €
+3,50%
16:05:54 Uhr
Handeln Depot/Watchlist
Aktienanzahl *
11,52 Mio.
Marktkapitalisierung *
22,59 Mio. €
Streubesitz
-
Index-Zugehörigkeit
-
IR-Website
zur Website
*Stand: 02.09.2023

Palatin Technologies News

02.05.24 - PR Newswire
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity
Palatin Announces FDA Clearance of IND Application for the Co-​Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity PR Newswire
30.04.24 - PR Newswire
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 ...
08.04.24 - PR Newswire
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024
Palatin Announces Phase 3 PL9643 MELODY-1 Dry Eye Disease (DED) Clinical Data Results Presented at American Society of Cataract and Refractive Surgery (ASCRS) 2024 PR ...
28.02.24 - PR Newswire
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Announces Results of PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire
15.02.24 - PR Newswire
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire
09.02.24 - PR Newswire
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024
Palatin to Report Second Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on February 15, 2024 PR Newswire
05.02.24 - PR Newswire
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED)
Palatin Announces Database Lock for PL9643 MELODY-1 Pivotal Phase 3 Clinical Trial in Patients with Dry Eye Disease (DED) PR Newswire
01.02.24 - PR Newswire
Palatin Announces Closing of $10 Million Registered Direct Offering
Palatin Announces Closing of $10 Million Registered Direct Offering PR Newswire
30.01.24 - PR Newswire
Thinking about buying stock in Arcus Biosciences, Palatin Technologies, Exxon Mobil, Archer Aviation, or Sidus Space ?
Thinking about buying stock in Arcus Biosciences, Palatin Technologies, Exxon Mobil, Archer Aviation, or Sidus Space ? PR Newswire
30.01.24 - PR Newswire
Palatin Announces $10 Million Registered Direct Offering
Palatin Announces $10 Million Registered Direct Offering PR Newswire
08.01.24 - PR Newswire
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024
Palatin Provides Corporate Update and Highlights Strategic Priorities for Calendar Year 2024 PR Newswire
22.12.23 - PR Newswire
Thinking about buying stock in Macy's, Mullen Automotive, Lottery.com, Palatin Technologies, or Reviva Pharmaceuticals?
Thinking about buying stock in Macy's, Mullen Automotive, Lottery.com, Palatin Technologies, or Reviva Pharmaceuticals? PR Newswire
20.12.23 - PR Newswire
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million
Palatin Completes Sale of Vyleesi® to Cosette Pharmaceuticals for up to $171 Million PR Newswire
18.12.23 - PR Newswire
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American
Palatin Receives Notice of Acceptance of the Listing Standards Compliance Plan from NYSE American PR Newswire
14.11.23 - PR Newswire
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
Palatin Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update PR Newswire
09.11.23 - PR Newswire
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023 PR Newswire
24.10.23 - PR Newswire
Palatin Announces Closing of $5 Million Registered Direct Offering
Palatin Announces Closing of $5 Million Registered Direct Offering PR Newswire
23.10.23 - PR Newswire
Palatin Announces $5 Million Registered Direct Offering
Palatin Announces $5 Million Registered Direct Offering PR Newswire
19.10.23 - PR Newswire
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results
Palatin Announces Preliminary Quarter Ended September 30, 2023 Vyleesi® Product Revenue Results PR Newswire
18.10.23 - PR Newswire
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients
Palatin Announces Positive Preclinical Data Showing Synergistic Weight Loss; Initiating Clinical Study of Melanocortin 4 Receptor Agonist + GLP-1 in Obese Patients PR Newswire

Newssuche

Videos

08:55 Uhr -6,48%
Technical Trading: Rohöl Short Chance
Rohöl Short Typ: Turbo Open End WKN: VD4JF9 Hebel: 13 Laufzeit: OpenEnd Einstieg: Market ... Mehr »